Cartagena

Researchers are evaluating molnupiravir, an oral medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 in people at high risk of disease progression. The study focuses on adults with confirmed COVID-19 infection who are at increased risk due to age, medical conditions, or other factors. This is a Phase 3 randomized, placebo-controlled, double-blind clinical trial led by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either molnupiravir or a matching placebo. Those in the molnupiravir group will take 800 mg orally every 12 hours for 5 days, totaling 10 doses. The same dosing schedule applies to the placebo group. Some participants may also receive remdesivir as part of standard care if clinically appropriate. During the study, participants will be monitored for up to 29 days to assess outcomes such as hospitalization, death, or medically attended visits related to COVID-19. Safety will be evaluated by tracking adverse events and discontinuation due to side effects. Researchers will also measure symptom relief, viral RNA levels, and other health indicators. The study is expected to continue until January 2031.

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Parkinsons disease PD is a neurological disorder that affects the brain, causing symptoms like tremors, stiffness, and slow movement. This research evaluates changes in sleep disturbances among adults with advanced Parkinsons disease who are receiving subcutaneous FoslevodopaFoscarbidopa as part of their routine care. The study includes about 103 adults across approximately 20 sites in Spain. Participants will receive subcutaneous infusion of FoslevodopaFoscarbidopa prescribed by their doctors according to local guidelines. The treatment is given as part of routine clinical practice without additional study procedures. The study follows participants for up to 12 weeks while they continue their prescribed therapy. During the study, participants will attend regular hospital or clinic visits as part of their usual care, with no extra burden from the trial. Researchers will assess changes in sleep disturbances using the Parkinsons Disease Sleep Scale - 2 PDSS-2 over approximately 12 weeks. The study focuses on observing outcomes without altering standard treatment and monitoring participants throughout this period.

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating whether continuing cetuximab treatment beyond first-line progression can improve outcomes in adults with metastatic colorectal cancer who have tumors that are RAS and BRAF wild-type. This Phase 3 clinical trial aims to compare chemotherapy combined with cetuximab versus chemotherapy combined with bevacizumab, focusing on tumor response, progression-free survival, overall survival, and safety. The study builds on prior trials suggesting potential benefits of cetuximab continuation in this patient group. Participants will be randomly assigned to receive either FOLFOX or FOLFIRI chemotherapy combined with cetuximab experimental group or bevacizumab control group. Treatments are given every two weeks, with cetuximab administered as a 120-minute intravenous infusion at 500 mgm and bevacizumab at 5 mgkg. Therapy continues until disease progression, unacceptable side effects, or patient withdrawal. Tumor response will be assessed by independent review using RECIST criteria. During the study, patients undergo regular CT or MRI scans, laboratory tests, and clinical evaluations. Biological samples such as tumor tissue, blood, and stool are collected for research on resistance mechanisms and the gut microbiome. The primary measure is the overall response rate assessed up to 48 months, with secondary outcomes including overall survival, progression-free survival, and safety monitored throughout treatment and up to 30 days after the last dose. Participation lasts through treatment and follow-up periods up to several years.

Researchers are developing and validating a predictive model to understand the risk of acquiring sexually transmitted infections STIs among individuals using HIV pre-exposure prophylaxis PrEP within Spains national program. This observational study includes PrEP users followed according to national protocols at 23 hospitals. The study focuses on STIs such as syphilis, gonorrhea, chlamydia, herpes, hepatitis, HIV, and MPOX, with the primary outcome being whether participants develop an STI. Participants are individuals who have started daily oral PrEP, have taken at least one pill, and meet the approved criteria by Spanish guidelines. They will be monitored quarterly with tests including blood samples and swabs from various sites to diagnose STIs. The study uses data from these visits to build and validate predictive models and analyze factors linked to STI acquisition. Participants will be followed over an average of five years with regular clinical visits to monitor for STIs and collect behavioral and adherence data. Researchers will measure the occurrence and number of STIs, changes in behavior, PrEP adherence, and discontinuation rates. The study aims to improve understanding of STI dynamics among PrEP users while ensuring ongoing monitoring and data collection throughout the participation period.

Researchers are collecting real-world data from cancer patients who receive radiotherapy to better understand the role of radiation oncology within a multidisciplinary treatment approach. This open-ended, prospective, non-interventional study aims to support radiotherapy research by observing patients over time without providing therapeutic interventions. The study includes patients with various cancer types who are planned to receive radiotherapy. Participants include patients treated with radical radiotherapy for oligometastatic disease as well as those receiving high-dose re-irradiation. The study is organized into multiple cohorts, such as OligoCare and ReCare, based on the type of radiotherapy treatment. Since it is an observational study, no experimental treatments or placebos are given. During the study, researchers will collect data on patient outcomes including disease-free survival, loco-regional control, distant metastasis-free survival, overall survival, and any adverse events related to radiotherapy over a period of five years. The main measure is the number of patients treated with radiotherapy enrolled in the program. Participants will have their health and treatment effects monitored regularly throughout this timeframe to provide valuable information about radiotherapy outcomes in real-world clinical settings.

Researchers are evaluating a smartphone app called Digital Solution for Pain in Adolescents Digital SPA designed to help children and adolescents aged 12 to 17 years who have chronic pain. This study aims to co-develop the app with patients, test its usability, and implement it as a tool to provide pain management resources and prevent future disability. The study is divided into multiple phases including focus groups, content creation, and an effectiveness and implementation study. The intervention uses validated psychological methods, especially Cognitive Behavioral Therapy and Acceptance and Commitment Therapy, to teach pain coping skills such as relaxation, goal setting, sleep management, behavioral activation, self-management of negative thoughts and emotions, and communication skills. Participants will be randomly assigned to either use the Digital SPA app or receive usual care at their hospital. The app was co-created with patients based on their input and current evidence-based guidelines. Participants will take part in individual and group interviews, complete online questionnaires, and use the smartphone app during the study. Researchers will measure changes in pain interference, emergency room visits due to pain, pain readiness to change, medication use, emotional distress, functional disability, sleep quality, pain self-efficacy, psychological flexibility, treatment satisfaction, and adherence over several time points from before treatment, mid-treatment, post-treatment, and at a 3-month follow-up. The total study duration includes an 8-week treatment period and follow-up assessments at 3 months after treatment completion.

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.

Researchers are evaluating a structured multidisciplinary approach called iABC to improve the management of elderly patients with atrial fibrillation AF who have multiple long-term health conditions. This study aims to compare the iABC approach with usual clinical care to see if it leads to better clinical outcomes and quality of life. The iABC strategy focuses on three key areas preventing stroke with appropriate anticoagulation, improving symptom control, and optimizing treatment of related heart and other health conditions. The trial is conducted across several European countries including Bulgaria, Denmark, Italy, Romania, Serbia, and Spain. The study is designed as a cluster randomized trial where participating centers are assigned either to implement the iABC platform or continue their usual care practices. The iABC platform combines an educational program, a healthy diet and physical activity plan, guideline-based medication management, and regular patient reassessments. Doctors using iABC can monitor patient data and provide personalized advice on treatments and lifestyle throughout the study. Centers in the control group will manage patients according to their local standard care guidelines. Participants will be followed for at least 12 months to assess the impact of iABC on outcomes such as unplanned hospitalizations, stroke and cardiovascular events, physical activity levels, patient engagement, and medication adherence. The study includes regular data collection to monitor these factors and assess adherence to the iABC care pathway. This approach aims to provide clear evidence about whether a holistic, integrated care model can improve health and quality of life in older adults with AF and multiple health issues.